Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"S. Korea's Green Cross seeks phase 2 trials of COVID-19 plasma drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Green Cross Lab Cell

    Menu

    Green Cross Lab Cell

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Green Cross Lab Cell

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              S. Korea's Green Cross seeks phase 2 trials of COVID-19 plasma drug

              Details:

              The Phase II trials of an experimental COVID-19 blood plasma treatment drug would review the safety and efficacy of the drug in 60 domestic patients in five hospitals.

              Lead Product(s): GC5131A

              Therapeutic Area: Infections and Infectious Diseases Product Name: GC5131A

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Green Cross Lab Cell

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC)

              Details:

              Kleo's first non-oncology application of its antibody recruiting molecule (ARM™) to be tested in combination with GCLC'S NK cells as a potential COVID-19 therapeutic.

              Lead Product(s): NK cell therapy,Antibody recruiting molecule

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Kleo Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY